Amgen stock gains as William Blair reiterates Outperform on positive cancer trial

Amgen announced positive top-line Phase III results for bemarituzumab in first-line gastric cancer, demonstrating significant overall survival improvement, while its experimental obesity drug MariTide showed promising Phase 2 efficacy with up to 20% weight loss and cardiometabolic benefits, prompting its progression to Phase 3. These key pipeline advancements, coupled with Amgen's robust financial health and strong existing portfolio, underpin analyst optimism and are expected to drive future growth, despite full efficacy and safety data for bemarituzumab awaiting detailed disclosure.

Analysis

Amgen has delivered significant positive updates on two key pipeline assets, bolstering its long-term growth outlook. The company announced its Phase III FORTITUDE-101 study for bemarituzumab met its primary endpoint of improving overall survival in first-line gastric cancer, a notable achievement in a difficult-to-treat indication. While specific data remains undisclosed pending a future medical conference, this top-line success is a major de-risking event. Concurrently, Amgen's experimental obesity treatment, MariTide, demonstrated promising Phase 2 results, including up to 20% weight loss and cardiometabolic benefits, and is now advancing to a Phase 3 program. These clinical milestones are supported by Amgen's robust financial foundation, which includes $34.1 billion in revenue over the last twelve months, a 69% gross profit margin, and a 15-year track record of consistent dividend payments. Analyst firm William Blair reiterated its Outperform rating, citing not only the pipeline's potential but also revenue upside from existing commercial assets like Repatha and Imdelltra. However, critical data points for bemarituzumab, particularly ocular adverse event and discontinuation rates, are yet to be revealed and will be crucial in assessing its ultimate market opportunity. The wide range of analyst price targets, from $185 to $400, reflects this blend of high potential and pending data validation.

Key Decisions for Investors

• The positive top-line results from both the bemarituzumab oncology trial and the MariTide obesity study materially strengthen Amgen's late-stage pipeline, warranting a re-evaluation of the company's long-term growth trajectory.
• Investors should closely monitor the upcoming medical conference for the full bemarituzumab data, with a specific focus on safety metrics like ocular adverse events, as this will be a key determinant of the drug's commercial potential and could significantly impact valuation.
• Given that the stock is flagged as potentially undervalued and backed by strong fundamentals and consistent capital returns, the current clinical momentum presents a compelling argument, but investors should also watch for results from the second Phase III gastric cancer study (FORTITUDE-102) in the second half of the year for further catalysts.